TY - JOUR
T1 - Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men
T2 - A cohort study
AU - Grant, Robert M.
AU - Anderson, Peter L.
AU - McMahan, Vanessa
AU - Liu, Albert
AU - Amico, K. Rivet
AU - Mehrotra, Megha
AU - Hosek, Sybil
AU - Mosquera, Carlos
AU - Casapia, Martin
AU - Montoya, Orlando
AU - Buchbinder, Susan
AU - Veloso, Valdilea G.
AU - Mayer, Kenneth
AU - Chariyalertsak, Suwat
AU - Bekker, Linda Gail
AU - Kallas, Esper G.
AU - Schechter, Mauro
AU - Guanira, Juan
AU - Bushman, Lane
AU - Burns, David N.
AU - Rooney, James F.
AU - Glidden, David V.
N1 - Funding Information:
We are grateful to the study participants for their trust that research could improve their lives, to the US National Institutes for Health for grant support, to Gilead Sciences for donation of FTC/TDF, to FHI360 and the HIV Prevention Trials Network for grants management, to John Carroll for graphics composition, and to Malu Robles for administrative support. The iPrEx study team includes the authors of this report and the following people: Pedro Goicochea, Robert Hance, Patricia Defechereux, Jeff McConnell, Christopher Eden, Jeanny Lee, Deirdre Devine, Marc Solomon (Gladstone); Kimberly Koester, Kathleen Mulligan, Teri Liegler (UCSF); Beatriz Grinsztejn, Brenda Hoagland (FIOCRUZ); Zelinda Maria Bartolomei Nakagawa, Natalia Barros Cerqueira (USP); Juan Carlos Hinojosa Boyer, Lilian Saavedra Sevillano (ACSA); Lorena Vargas, John McRae (INMENSA); Hailey Gilmore, Elizabeth Faber (SFDPH); Jaime Martinez, Kristine Santos (CORE/Stroger); Benjamin Brown, Peter Chodacki (Desmond Tutu Health Foundation); Carina Beppu Yoshida, Monica Barbosa de Souza (Praca Onze); Marcy Gelman, Chris Chianese (Fenway); Demetrio Magallanes, Luis Fernando Galarza (Equidad); Pongpun Saokhieo, Natthapol Kosashunhanan (RIHES); Brian Postle, Lisa Ondrejcek, Darryl Pahl (DF/Net data management); Brandon Klein, Anthony Guida, Becky Kerr, Kevin McAllister, and Kayla Bushman (University of Colorado, Colorado Antiviral Pharmacology Laboratory).
PY - 2014/9
Y1 - 2014/9
N2 - Background: The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a cohort of HIV-negative people at risk of infection. Methods: In our cohort study, men and transgender women who have sex with men previously enrolled in PrEP trials (ATN 082, iPrEx, and US Safety Study) were enrolled in a 72 week open-label extension. We measured drug concentrations in plasma and dried blood spots in seroconverters and a random sample of seronegative participants. We assessed PrEP uptake, adherence, sexual practices, and HIV incidence. Statistical methods included Poisson models, comparison of proportions, and generalised estimating equations. Findings: We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP. Uptake was higher among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0·003) and having serological evidence of herpes (612/791 [77%] vs 613/812 [75%] p=0·03). Of those receiving PrEP, HIV incidence was 1·8 infections per 100 person-years, compared with 2·6 infections per 100 person-years in those who concurrently did not choose PrEP (HR 0·51, 95% CI 0·26-1·01, adjusted for sexual behaviours), and 3·9 infections per 100 person-years in the placebo group of the previous randomised phase (HR 0·49, 95% CI 0·31-0·77). Among those receiving PrEP, HIV incidence was 4·7 infections per 100 person-years if drug was not detected in dried blood spots, 2·3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0·6 per 100 person-years for use of two to three tablets per week, and 0·0 per 100 person-years for use of four or more tablets per week (p<0·0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes. Interpretation: PrEP uptake was high when made available free of charge by experienced providers. The effect of PrEP is increased by greater uptake and adherence during periods of higher risk. Drug concentrations in dried blood spots are strongly correlated with protective benefit.
AB - Background: The effect of HIV pre-exposure prophylaxis (PrEP) depends on uptake, adherence, and sexual practices. We aimed to assess these factors in a cohort of HIV-negative people at risk of infection. Methods: In our cohort study, men and transgender women who have sex with men previously enrolled in PrEP trials (ATN 082, iPrEx, and US Safety Study) were enrolled in a 72 week open-label extension. We measured drug concentrations in plasma and dried blood spots in seroconverters and a random sample of seronegative participants. We assessed PrEP uptake, adherence, sexual practices, and HIV incidence. Statistical methods included Poisson models, comparison of proportions, and generalised estimating equations. Findings: We enrolled 1603 HIV-negative people, of whom 1225 (76%) received PrEP. Uptake was higher among those reporting condomless receptive anal intercourse (416/519 [81%] vs 809/1084 [75%], p=0·003) and having serological evidence of herpes (612/791 [77%] vs 613/812 [75%] p=0·03). Of those receiving PrEP, HIV incidence was 1·8 infections per 100 person-years, compared with 2·6 infections per 100 person-years in those who concurrently did not choose PrEP (HR 0·51, 95% CI 0·26-1·01, adjusted for sexual behaviours), and 3·9 infections per 100 person-years in the placebo group of the previous randomised phase (HR 0·49, 95% CI 0·31-0·77). Among those receiving PrEP, HIV incidence was 4·7 infections per 100 person-years if drug was not detected in dried blood spots, 2·3 infections per 100 person-years if drug concentrations suggested use of fewer than two tablets per week, 0·6 per 100 person-years for use of two to three tablets per week, and 0·0 per 100 person-years for use of four or more tablets per week (p<0·0001). PrEP drug concentrations were higher among people of older age, with more schooling, who reported non-condom receptive anal intercourse, who had more sexual partners, and who had a history of syphilis or herpes. Interpretation: PrEP uptake was high when made available free of charge by experienced providers. The effect of PrEP is increased by greater uptake and adherence during periods of higher risk. Drug concentrations in dried blood spots are strongly correlated with protective benefit.
UR - http://www.scopus.com/inward/record.url?scp=84906793896&partnerID=8YFLogxK
U2 - 10.1016/S1473-3099(14)70847-3
DO - 10.1016/S1473-3099(14)70847-3
M3 - Article
C2 - 25065857
AN - SCOPUS:84906793896
SN - 1473-3099
VL - 14
SP - 820
EP - 829
JO - The Lancet Infectious Diseases
JF - The Lancet Infectious Diseases
IS - 9
ER -